Memphasys Ltd
ASX:MEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Memphasys Ltd
Accumulated Depreciation
Memphasys Ltd
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Memphasys Ltd
ASX:MEM
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genetic Technologies Ltd
ASX:GTG
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Accumulated Depreciation
-AU$3.5m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Accumulated Depreciation
-AU$30.8m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Accumulated Depreciation
-AU$4.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Accumulated Depreciation
-AU$392.9k
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Memphasys Ltd
Glance View
Memphasys Ltd. is a life sciences company. The company is headquartered in Homebush West, New South Wales. The company went IPO on 2007-05-14. The company develops medical devices, diagnostics and media with application to assists reproduction technologies in humans and animals. The Company’s lead product is Felix device. The Felix is an automated device for separating quality sperm from a semen sample for the use in human in vitro fertilization (IVF) procedures. The firm's membrane technology utilizes its separation technology along with its multiple devices and hydrogel membranes to fractionate biological molecules. The technology relies on the applied electric field and charged biological molecules. The sample and harvest chamber are formed by placing the separation membrane in between two restriction membranes with restricted pores.
